1 follower
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Their goal is to improve the response rate of patients to current and future immunotherapy medicines.
Industries
Headquarters
Stage
Employees
Links
View full screen
Charles McDermott
View all
8 members
6 members
4 members
3 members
Kymera Therapeutics
3 followers
Cartesian Therapeutics
Tempus Labs
12 followers
Ultragenyx Pharmaceutical
5 followers
Biogen
93 followers
Explore more companies